# Association between NKILA and some apoptotic gene expression in atherosclerosis

**Authors:** Burcu Bayyurt, Şeyda Akın, Nil Özbilüm Şahin, İzzet Yelkuvan

PMC · DOI: 10.7717/peerj.17915 · 2024-08-21

## TL;DR

This study explores how the lncRNA NKILA affects apoptosis-related genes in endothelial cells exposed to ox-LDL, which is linked to atherosclerosis.

## Contribution

The study reveals a novel regulatory role of NKILA in modulating apoptotic gene expression in atherosclerosis.

## Key findings

- NKILA gene silencing downregulates BAX, CASP9, CYCS, APAF1, and BCL-2 gene expression in HUVEC cells.
- Higher NKILA expression correlates with increased Cq values of apoptotic genes, indicating a regulatory relationship.
- The findings suggest NKILA may influence endothelial cell apoptosis in atherosclerosis.

## Abstract

Oxidized light-density lipoprotein (ox-LDL) causes endothelial dysfunction, which is an important determinant of atherogenesis, and subsequently leads to apoptosis. Atherosclerosis is one of the most significant cardiovascular diseases (CVDs) threatening human health and causes death worldwide. Recently, long noncoding RNAs (lncRNAs) have been suggested to involved in vascular biology. Ox-LDL activates nuclear factor kappa-B (NF-κB), and NF-κB interacting lncRNA (NKILA) inhibits NF-κB signaling. In this study, the hypothesis is that NKILA may regulate endothelial cell (EC) apoptosis and, therefore, play a role in the pathogenesis of atherosclerosis. This hypothesis is based on the knowledge that EC apoptosis contributes to atherosclerosis development and that NKILA has become a prominent lncRNA in CVDs. The expression of Bcl-2-associated X protein (BAX), caspase 9 (CASP9), cytochrome c (Cyt c, CYCS), apoptotic protease activating factor 1 (APAF1), and B-cell lymphoma 2 (BCL-2) genes in human umbilical vein endothelial cells (HUVEC) treated with ox-LDL and transfected with NKILA siRNA was analyzed using quantitative reverse transcription polymerase chain reaction (RT-qPCR). BAX, CASP9, CYCS, APAF1, and BCL-2 gene expression was downregulated in ox-LDL and NKILA siRNA-treated HUVEC. In addition, when threshold/quantification cycle (Cq) values of NKILA gene expression increased, Cq values of BAX, CASP9, APAF1, and BCL-2 gene expression increased statistics significantly. The expression detection of all these genes, resulting from NKILA gene silencing, may provide guidance for epigenetic studies on EC apoptosis in atherosclerosis.

## Linked entities

- **Genes:** NKILA (NF-kappaB interacting lncRNA) [NCBI Gene 105416157], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], CASP9 (caspase 9) [NCBI Gene 842], CYCS (cytochrome c, somatic) [NCBI Gene 54205], APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), Cyt-c-d (Cytochrome c distal)
- **Diseases:** atherosclerosis (MONDO:0005311)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, NKILA (NF-kappaB interacting lncRNA) [NCBI Gene 105416157], CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** endothelial dysfunction (MESH:D014652), Atherosclerosis (MESH:D050197), death (MESH:D003643), CVDs (MESH:D002318)
- **Chemicals:** Oxidized light-density lipoprotein (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11344533/full.md

---
Source: https://tomesphere.com/paper/PMC11344533